A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare

MLA

Samuel Hall, et al. “A Prospective Study of Nucleot(s)Ide Analogue Discontinuation in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B Patients: Interim Analysis at Week 48 Demonstrates Profound Reductions of HBsAg Associated with ALT Flare.” Journal of Hepatology, vol. 73, Aug. 2020, pp. S69–70. EBSCOhost, https://doi.org/10.1016/s0168-8278(20)30674-7.

APA

Samuel Hall, Gareth Burns, Miriam Levy, John Lubel, Amanda Nicoll, Gail Matthews, Paul Desmond, William Sievert, Scott Bowden, Stephen Locarnini, Jacinta Holmes, Kumar Visvanathan, & Alexander Thompson. (2020). A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare. Journal of Hepatology, 73, S69–S70. https://doi.org/10.1016/s0168-8278(20)30674-7

Chicago

Samuel Hall, Gareth Burns, Miriam Levy, John Lubel, Amanda Nicoll, Gail Matthews, Paul Desmond, et al. 2020. “A Prospective Study of Nucleot(s)Ide Analogue Discontinuation in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B Patients: Interim Analysis at Week 48 Demonstrates Profound Reductions of HBsAg Associated with ALT Flare.” Journal of Hepatology 73 (August): S69–70. doi:10.1016/s0168-8278(20)30674-7.